Press Detail





Biotest AG:Biotest remains successful

Biotest AG / Miscellaneous

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------

Biotest remains successful

§ Sales and EBIT in the first half of 2009 significantly increased compared
to previous year's figures
§ Important progress made in R&D projects

Dreieich, 12 August 2009. The Biotest Group once again reported profitable
growth in the first half of 2009. The company which specialises in
pharmaceuticals, biotherapeutics and diagnostics reported sales of EUR239.2
million in the first six months of the year 2009, up by 13.4% versus the
first half of 2008 (EUR210.9 million).
At EUR29.4 million, earnings before interest and taxes (EBIT) were 6.5%
higher than in the first half of the previous year (EUR27.6 million).
Earnings per share increased by 11.6% from EUR1.12 to EUR1.25 compared to
the previous year.
Biotest has advanced with a number of projects that are key to the further
strategic development of the company. Interim analyses of the ongoing
studies on the development of monoclonal antibodies (mAb) have revealed
further encouraging data on the efficacy and tolerability of BT-061.
In light of the financial and economic crisis, Biotest has stepped up its
risk control and management activities, and is keeping a very close eye on
the situation on the markets. The company expects the macroeconomic
situation to have an impact on the prices that can be achieved on some
markets, but does not predict any major downward spiral in prices. The
Management Board has confirmed its sales and earnings targets for financial
year 2009.
More details on sales and earnings of the four segments as well as on
progress of the implementation achieved in strategically important projects
are given in Biotest's Half-year Report. The Half-year Report can be seen
and downloaded on Biotest's website (www.biotest.com).

Investor Relations Biotest AG
Dr. Monika Buttkereit
Telefon: +49 (0) 6103 801-4406
E-Mail: investor_relations@biotest.de

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.com


Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest

Biotest is a company that researches and manufactures pharmaceutical,
biotherapeutic and diagnostic products and has specialised in the areas of
application of immunology and haematology. In its Plasma Protein segment,
Biotest develops and markets immunoglobulins, coagulation factors and
albumins based on human blood plasma. These are used for diseases of the
immune and haematopoietic systems. In the Biotherapeutic segment, Biotest
researches into the clinical development of monoclonal antibodies,
including in the indications of rheumatoid arthritis and cancer of plasma
cells. The products of the Microbiological Monitoring segment are primarily
used in hygiene monitoring, while those of Medical Diagnostics are used,
for example, in blood transfusions and transplants. Biotest has more than
2,000 employees worldwide. The shares of Biotest AG are listed in the SDAX
on the Frankfurt stock exchange.


Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard/Official traded
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart 
12.08.2009  Financial News transmitted by DGAP
----------------------------------------------------------------------
 
Language:     English
Issuer:       Biotest AG
              Landsteinerstraße 5
              63303 Dreieich
              Deutschland
Phone:        0 61 03 - 8 01-0
Fax:          0 61 03 - 8 01-150
E-mail:       investor_relations@biotest.de
Internet:     http://www.biotest.de
ISIN:         DE0005227235, DE0005227201
WKN:          522723, 522720
Indices:      SDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, Stuttgart
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------